Table of Contents
Advances in Nephrology
Volume 2014, Article ID 538392, 10 pages
http://dx.doi.org/10.1155/2014/538392
Research Article

Calcium Carbonate versus Sevelamer Hydrochloride as Phosphate Binders after Long-Term Disease Progression in 5/6 Nephrectomized Rats

1School of Medicine, University of Tampere, 33014 Tampere, Finland
2Department of Ophthalmology, Tampere University Hospital, P.O. Box 2000, 33521 Tampere, Finland
3Department of Clinical Chemistry, Etelä-Pohjanmaa Central Hospital Laboratory, 60220 Seinäjoki, Finland
4Department of Pharmacology and Toxicology, Biocenter Oulu, University of Oulu, P.O. Box 5000, 99014 Oulu, Finland
5Department of Internal Medicine, Tampere University Hospital, P.O. Box 2000, 33521 Tampere, Finland

Received 17 May 2014; Revised 2 July 2014; Accepted 5 August 2014; Published 24 August 2014

Academic Editor: Carlos G. Musso

Copyright © 2014 Suvi Törmänen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. N. Foley, P. S. Parfrey, and M. J. Sarnak, “Epidemiology of cardiovascular disease in chronic renal disease,” Journal of the American Society of Nephrology, vol. 9, no. 12, pp. S16–S23, 1998. View at Google Scholar · View at Scopus
  2. G. M. Chertow, P. Raggi, S. Chasan-Taber, J. Bommer, H. Holzer, and S. K. Burke, “Determinants of progressive vascular calcification in haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 19, no. 6, pp. 1489–1496, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. S. D. Navaneethan, S. C. Palmer, M. Vecchio, J. C. Craig, G. J. Elder, and G. F. Strippoli, “Phosphate binders for preventing and treating bone disease in chronic kidney disease patients,” Cochrane Database of Systematic Reviews, vol. 2, Article ID CD006023, 2011. View at Google Scholar · View at Scopus
  4. L. Wang, J. E. Manson, and H. D. Sesso, “Calcium intake and risk of cardiovascular disease: a review of prospective studies and randomized clinical trials,” American Journal of Cardiovascular Drugs, vol. 12, no. 2, pp. 105–116, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Eräranta, A. Riutta, M. Fan et al., “Dietary phosphate binding and loading alter kidney angiotensin-converting enzyme mRNA and protein content in 5/6 nephrectomized rats,” American Journal of Nephrology, vol. 35, no. 5, pp. 401–408, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Pörsti, M. Fan, P. Kööbi et al., “High calcium diet down-regulates kidney angiotensin-converting enzyme in experimental renal failure,” Kidney International, vol. 66, no. 6, pp. 2155–2166, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Eräranta, S. Törmänen, P. Kööbi et al., “Phosphate binding reduces aortic Angiotensin-converting enzyme and enhances nitric oxide bioactivity in experimental renal insufficiency,” American Journal of Nephrology, vol. 39, pp. 400–408, 2014. View at Google Scholar
  8. K. Caglar, M. I. Yilmaz, M. Saglam et al., “Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 1, pp. 61–68, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Brezina, W. Y. Qunibi, and C. R. Nolan, “Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications,” Kidney International, vol. 66, no. 90, pp. S39–S45, 2004. View at Google Scholar · View at Scopus
  10. S. Mathew, R. J. Lund, F. Strebeck, K. S. Tustison, T. Geurs, and K. A. Hruska, “Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy,” Journal of the American Society of Nephrology, vol. 18, no. 1, pp. 122–130, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Tokumoto, M. Mizobuchi, J. L. Finch, H. Nakamura, D. R. Martin, and E. Slatopolsky, “Blockage of the renin-angiotensin system attenuates mortality but not vascular calcification in uremic rats: sevelamer carbonate prevents vascular calcification,” The American Journal of Nephrology, vol. 29, no. 6, pp. 582–591, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Kawashima, J. A. Kraut, and K. Kurokawa, “Metabolic acidosis suppresses 25-hydroxyvitamin D3-1α-hydroxylase in the rat kidney. Distinct site and mechanism of action,” The Journal of Clinical Investigation, vol. 70, no. 1, pp. 135–140, 1982. View at Publisher · View at Google Scholar · View at Scopus
  13. S. W. Lee, J. Russell, and L. V. Avioli, “25 Hydroxycholecalciferol to 1,25 dihydroxycholecalciferol: conversion impaired by systemic metabolic acidosis,” Science, vol. 195, no. 4282, pp. 994–996, 1977. View at Publisher · View at Google Scholar · View at Scopus
  14. A. J. Brown, A. Dusso, and E. Slatopolsky, “Vitamin D,” American Journal of Physiology, vol. 277, no. 2, pp. F157–F175, 1999. View at Google Scholar · View at Scopus
  15. D. A. Bushinsky, “The contribution of acidosis to renal osteodystrophy,” Kidney International, vol. 47, no. 6, pp. 1816–1832, 1995. View at Publisher · View at Google Scholar · View at Scopus
  16. F. J. Mendoza, I. Lopez, A. Montes De Oca, J. Perez, M. Rodriguez, and E. Aguilera-Tejero, “Metabolic acidosis inhibits soft tissue calcification in uremic rats,” Kidney International, vol. 73, no. 4, pp. 407–414, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. G. J. Behets, M. Gritters, G. Dams, M. E. De Broe, and P. C. D'Haese, “Effects of efficient phosphate binding on bone in chronic renal failure rats,” Renal Failure, vol. 27, no. 4, pp. 475–484, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Katsumata, K. Kusano, M. Hirata et al., “Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats,” Kidney International, vol. 64, no. 2, pp. 441–450, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Kuwahara, S. Inoshita, Y. Terada, and S. Sasaki, “Effect of sevelamer hydrochloride on bone in experimental uremic rats,” Therapeutic Apheresis and Dialysis, vol. 13, no. 1, pp. 42–48, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Nagano, S. Miyata, M. Abe et al., “Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats,” Kidney International, vol. 69, no. 3, pp. 531–537, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Nagano, S. Miyata, M. Abe, S. Wakita, N. Kobayashi, and M. Wada, “Sevelamer hydrochloride reverses parathyroid gland enlargement via regression of cell hypertrophy but not apoptosis in rats with chronic renal insufficiency,” Nephrology Dialysis Transplantation, vol. 21, no. 3, pp. 634–643, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Nagano, S. Miyata, S. Obana et al., “Renal mineral handling in normal rats treated with sevelamer hydrochloride (Renagel), a noncalcemic phosphate binder,” Nephron, vol. 89, no. 3, pp. 321–328, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Nagano, S. Miyata, S. Obana et al., “Sevelamer hydrochloride, a calcium-free phosphate binder, inhibits parathyroid cell proliferation in partially nephrectomized rats,” Nephrology Dialysis Transplantation, vol. 18, supplement 3, pp. iii81–iii85, 2003. View at Google Scholar · View at Scopus
  24. N. Nagano, S. Miyata, S. Obana et al., “Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency,” Nephrology Dialysis Transplantation, vol. 18, no. 10, pp. 2014–2023, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. N. Nagano, S. Miyata, S. Obana et al., “Sevelamer hydrochloride (Renagel), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency,” Nephrology Dialysis Transplantation, vol. 16, no. 9, pp. 1870–1878, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. I. G. Nikolov, N. Joki, T. Nguyen-Khoa et al., “Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice,” Nephrology Dialysis Transplantation, vol. 27, no. 2, pp. 505–513, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. O. Phan, O. Ivanovski, T. Nguyen-Khoa et al., “Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice,” Circulation, vol. 112, no. 18, pp. 2875–2882, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. D. P. Rosenbaum, S. R. Holmes-Farley, W. H. Mandeville, M. Pitruzzello, and D. I. Goldberg, “Effect of RenaGel(TM), a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats,” Nephrology Dialysis Transplantation, vol. 12, no. 5, pp. 961–964, 1997. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Terai, H. Nara, K. Takakura et al., “Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels,” British Journal of Pharmacology, vol. 156, no. 8, pp. 1267–1278, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. Renvela Prescribing Information,” http://www.renvela.com/docs/pdf/RV382_Renvela_PI_08.2011.pdf.
  31. W. Braunlin, E. Zhorov, A. Guo et al., “Bile acid binding to sevelamer HCl,” Kidney International, vol. 62, no. 2, pp. 611–619, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Pierce, S. Hossack, L. Poole et al., “The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol,” Nephrology Dialysis Transplantation, vol. 26, no. 5, pp. 1615–1621, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Cozzolino, A. S. Dusso, H. Liapis et al., “The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats,” Journal of the American Society of Nephrology, vol. 13, no. 9, pp. 2299–2308, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Cozzolino, M. E. Staniforth, H. Liapis et al., “Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia,” Kidney International, vol. 64, no. 5, pp. 1653–1661, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Saito, A. Maeda, S. Ohtomo et al., “Circulating FGF-23 is regulated by 1α,25-dihydroxyvitamin D3 and phosphorus in vivo,” The Journal of Biological Chemistry, vol. 280, no. 4, pp. 2543–2549, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Magga, J. Kalliovalkama, H. Romppanen et al., “Differential regulation of cardiac adrenomedullin and natriuretic peptide gene expression by AT1 receptor antagonism and ACE inhibition in normotensive and hypertensive rats,” Journal of Hypertension, vol. 17, no. 11, pp. 1543–1552, 1999. View at Publisher · View at Google Scholar · View at Scopus
  37. I. Lopez, E. Aguilera-Tejero, F. J. Mendoza et al., “Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol,” Journal of the American Society of Nephrology, vol. 17, no. 3, pp. 795–804, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. I. de Brito-Ashurst, M. Varagunam, M. J. Raftery, and M. M. Yaqoob, “Bicarbonate supplementation slows progression of CKD and improves nutritional status,” Journal of the American Society of Nephrology, vol. 20, no. 9, pp. 2075–2084, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. W. G. Goodman and L. D. Quarles, “Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics,” Kidney International, vol. 74, no. 3, pp. 276–288, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. R. E. laClair, R. N. Hellman, S. L. Karp et al., “Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States,” The American Journal of Kidney Diseases, vol. 45, no. 6, pp. 1026–1033, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. S. U. Nigwekar, I. Bhan, and R. Thadhani, “Ergocalciferol and cholecalciferol in CKD,” The American Journal of Kidney Diseases, vol. 60, no. 1, pp. 139–156, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. H. Taskapan, M. Wei, and D. G. Oreopoulos, “25(OH) vitamin D3 in patients with chronic kidney disease and those on dialysis: rediscovering its importance,” International Urology and Nephrology, vol. 38, no. 2, pp. 323–329, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. G. M. London, “Left ventricular hypertrophy: why does it happen?” Nephrology Dialysis Transplantation, vol. 18, no. 8, pp. v2–v4, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. S. G. Achinger and J. C. Ayus, “The role of vitamin D in left ventricular hypertrophy and cardiac function,” Kidney International, Supplement, vol. 67, no. 95, pp. S37–S42, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Faul, A. P. Amaral, B. Oskouei et al., “FGF23 induces left ventricular hypertrophy,” The Journal of Clinical Investigation, vol. 121, no. 11, pp. 4393–4408, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. K. A. Griffin, M. M. Picken, M. Churchill, P. Churchill, and A. K. Bidani, “Functional and structural correlates of glomerulosclerosis after renal mass reduction in the rat,” Journal of the American Society of Nephrology, vol. 11, no. 3, pp. 497–506, 2000. View at Google Scholar · View at Scopus
  47. H. N. Ibrahim and T. H. Hostetter, “The renin-aldosterone axis in two models of reduced renal mass in the rat,” Journal of the American Society of Nephrology, vol. 9, no. 1, pp. 72–76, 1998. View at Google Scholar · View at Scopus
  48. A. Eräranta, V. Kurra, A. M. Tahvanainen et al., “Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency,” Journal of Hypertension, vol. 26, no. 8, pp. 1661–1668, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. F. E. Karet, “Mechanisms in hyperkalemic renal tubular acidosis,” Journal of the American Society of Nephrology, vol. 20, no. 2, pp. 251–254, 2009. View at Publisher · View at Google Scholar · View at Scopus